RxDoctor Payments Data

Natesh Lingam, MD

Cardiovascular Disease · Mount Clemens, MINPI 1801005145

Payments from drug & device makers

$5,288in general payments, 2019–2025

Across 257 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$703
  • Novartis$521
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$514
  • Johnson & Johnson$402
  • E.r. Squibb & Sons, L.L.C.$389
  • Pfizer$347
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,288100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,288 in reported general payments places this provider in the 55th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$257,517
Medicare patients
1,135
Services billed
3,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban546$662,571
XareltoRivaroxaban134$162,807
EntrestoSacubitril/Valsartan124$147,586
JardianceEmpagliflozin118$131,637
Repatha SureclickEvolocumab40$47,265
Repatha SyringeEvolocumab19$29,051
Praluent PenAlirocumab12$17,843
FarxigaDapagliflozin Propanediol11$12,066
Metoprolol Succinate549$11,394
Rosuvastatin Calcium443$8,091
BrilintaTicagrelor14$7,523
Atorvastatin Calcium315$5,823
Losartan Potassium254$4,506
Torsemide264$3,741
Carvedilol254$3,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$347$662,571546 claims
Johnson & JohnsonXarelto$402$162,807134 claims
NovartisEntresto$521$147,586124 claims
Boehringer IngelheimJardiance$162$131,637118 claims
AstraZenecaFarxiga, Brilinta$73$19,58925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Mount Clemens

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →